Nucala and Corticosteroids Can Increase EGPA Remission

Recently, researchers sought to examine how Nucala (mepolizumab) affected disease progression in patients with eosinophilic granulomatosis with polyangiitis (EGPA), especially when used in conjunction with corticosteroids. According to ANCA Vasculitis…

Continue Reading Nucala and Corticosteroids Can Increase EGPA Remission
Ursodeoxycholic Acid Improves Outcomes of Intrahepatic Cholestasis of Pregnancy
source: pixabay.com

Ursodeoxycholic Acid Improves Outcomes of Intrahepatic Cholestasis of Pregnancy

According to MedPage Today, ursodeoxycholic acid significantly improves patient outcomes in relation to intrahepatic cholestasis of pregnancy. This rare liver disorder increases the risk of fetal issues, stillbirths, or preterm…

Continue Reading Ursodeoxycholic Acid Improves Outcomes of Intrahepatic Cholestasis of Pregnancy

Community is Essential for Lambert-Eaton Myasthenia Syndrome Patients During the Pandemic

Quarantine during COVID-19 has been difficult for everyone. It's socially isolating, mentally draining, and physically limiting. We all find community different places. But no matter where we find it, it…

Continue Reading Community is Essential for Lambert-Eaton Myasthenia Syndrome Patients During the Pandemic
EC Approves ADV7103 Marketing Authorization for dRTA
source: pixabay.com

EC Approves ADV7103 Marketing Authorization for dRTA

Recently, the European Commission (EC) approved a marketing authorization for ADV7103 (Sibnayal), the first approved treatment for patients with distal renal tubular acidosis (dRTA). In a news release, pharmaceutical company…

Continue Reading EC Approves ADV7103 Marketing Authorization for dRTA

Xywav for Idiopathic Hypersomnia Receives Priority Review and sNDA Acceptance

In a news release from April 2021, biopharmaceutical company Jazz Pharmaceuticals, Inc. ("Jazz") shared that the FDA accepted its supplemental New Drug Application (sNDA) for review in relation to Xywav,…

Continue Reading Xywav for Idiopathic Hypersomnia Receives Priority Review and sNDA Acceptance

Phase 3 Study for Primary Axillary Hyperhidrosis Has Demonstrated Positive Results

Brickell Biotech has just announced the findings from their Phase 3 study investigating the long-term efficacy and safety of sofpironium bromide gel for the treatment of primary axillary hyperhidrosis. Hyperhidrosis…

Continue Reading Phase 3 Study for Primary Axillary Hyperhidrosis Has Demonstrated Positive Results

Phase 2 Trial Shows Therapy Reduces Seizures in Dravet Syndrome and Lennox-Gastaut Syndrome

The American Academy of Neurology recently held their annual meeting virtually to discuss the latest research in Dravet Syndrome (DS) and Lennox-Gastaut Syndrome (LGS). This meeting was held April 17th through 22nd,…

Continue Reading Phase 2 Trial Shows Therapy Reduces Seizures in Dravet Syndrome and Lennox-Gastaut Syndrome